HOME
ABOUT
About US
Corporate culture
Company honor
Development course
PRODUCT
Drugs in the field of tumor-re
Drugs in other fields
Health care products
R&d innovation
R&d pipeline
R&d progress
Patient recruitment
NEWS
Company dynamics
Trade news
Academic exchanges
INVESTOR
Latest announcement
H&R
Job development
Talent recruitment
CONTACT
Notice
EN
CN
HOME
ABOUT
About US
Corporate culture
Company honor
Development course
PRODUCT
Drugs in the field of tumor-re
Drugs in other fields
Health care products
R&d innovation
R&d pipeline
R&d progress
Patient recruitment
NEWS
Company dynamics
Trade news
Academic exchanges
INVESTOR
INVESTOR
Latest announcement
H&R
Job development
Talent recruitment
CONTACT
Notice
Shengbai oral liquid (mixture) was included in the "Interpretation of Traditional Chinese Medicine Diagnosis and Treatment Plans and Paths"
2020-03-30
PREV
Shengbai oral liquid (mixture) was included in the textbook of "Hematology of Traditional Chinese Medicine".
NEXT
Mengyang Pharmaceutical announced the results of the Phase I registration clinical trial of DH001, the world's first oral cardioprotective agent (reducing doxorubicin cardiotoxicity), in China
Hot news
What kind of treatment is needed fo...
How much do you know about leukopen...
Shengbai Oral Liquid (Mixture) w...
Should leukopenia be discontinued i...
Meta-analysis of the efficacy of S...
Shengbai Oral Liquid: Progress a...
How to deal with leukopenia after c...
Should I stop chemotherapy if I h...